Lupin Takes A Step Closer To $1bn US Janumet Opportunity
More Than Two Dozen Firms Settled On Janumet, Januvia ANDA Products
Lupin is looking to be ready on day one to challenge Merck & Co’s Janumet (metformin/sitagliptin) treatment for type 2 diabetes, after the US Food and Drug Administration tentatively waved through its ANDA product.
